Results of Sun Pharma Q3: Net Benefit Up Up 15%; Income from Rs 13,675 crore
Sun Pharma Q3 Results: Sun Pharmaceutical industries on Friday said its included network profits increased 15 percent in Rs 2,903 crore in CoreCer Cerrorte Corrorta Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorte Corrorth Corrorate. The greater medicine reported benefits of RS 2,524 crore in October-Tituma final finance.
Total money from work increased to RS 13,675 crore in a third quarter compared to Rs 12,381 Crore in last year, the Sunamma said to the controlling fulfillment.
The company said his board announced the temporary division of Rs 10.5 per FY25 annual budget against Rs.50 annual budget of last year.
“Our performance in a quarter has indicated a roundurba development. Product sales in the Global Specialty – Global Special Sale,” Chairman of Sun Pharma and Director in charge of Dilip Shanghvi means.
“The benefit of our market in India is conducted by the growth of the industry leading volume.
Every company’s businesses are always well-properly well-properly stated by the future, Shanghvi said.
Mumbai-based drug manufacturer said the India’s sale of India was standing ERS 4,300 Crore in the quarter of December, the growth of 13.8 percent in the same amount of sale.
Billed sales in the US was USD 474 million quarter, Marginal Cifuzi compared to the last third quarter and accounting for about 30 percent of integrated sales.
The formal sales in the markets standing in USD 277 million in a third quarter, a 10 percent of the 17 percent of the compiled sales.
Similarly, sales worldwide (lines) marketing, without India, US and market markets, are 259 million for 219 million, 21 million years against the preceding funds.
External API sales (active medicines) were Rs 568 Crore in Q3FY25, increased by 21.8 percent over Q3 ago.
Sun Pharma shares end 0.12 Percentage lower than RS 1,7433.10 Phicate on the BSE.
